Comparison 2. Rho kinase inhibitor versus beta‐blocker.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Mean IOP changes from baseline	3	1415	Mean Difference (IV, Fixed, 95% CI)	0.66 [0.41, 0.91]
2.2 Total ocular adverse events (per person‐month) – incidence risk difference	4		Risk Difference (IV, Random, 95% CI)	0.21 [0.14, 0.27]
2.3 Total ocular adverse events (per person‐month) – subgroup analysis by levels of reporting threshold	4		Risk Difference (IV, Random, 95% CI)	0.21 [0.14, 0.27]
2.3.1 Reporting threshold ≥ 3%	2		Risk Difference (IV, Random, 95% CI)	0.22 [0.03, 0.41]
2.3.2 Reporting threshold ≥ 5%	2		Risk Difference (IV, Random, 95% CI)	0.20 [0.14, 0.26]
2.4 Conjunctival hyperemia as adverse event (per person‐month)*	4		Risk Difference (IV, Random, 95% CI)	0.07 [0.04, 0.11]
2.5 Ocular pain or irritation as adverse event (per person‐month)*	4		Risk Difference (IV, Random, 95% CI)	0.01 [‐0.01, 0.02]